Novartis

#Collaboration #Immunology #License agreement #Monte Rosa Therapeutics #Novartis

Novartis and Monte Rosa partner on molecular glue degraders

Monte Rosa Therapeutics and Novartis have agreed a global license agreement to advance VAV1 molecular glue degrader-based medicines (MGDs). The deal includes MRT-6160, which is currently in an ongoing Phase I study for immune-mediated conditions. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture… Read More

#Business & Investment #News

AI and robotics
#Artificial intelligence (AI) #Generate:Biomedicines #Novartis #Partnership #Therapeutic proteins

Novartis and Generate partner on AI-created protein therapeutics

Novartis and Generate:Biomedicines have announced a multi-target collaboration to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate’s generative AI platform, ​‘The Generate Platform’, to create potentially first- and best-in-class molecules through AI-based optimisation and de novo generation. The collaboration will combine The Generate Platform, which… Read More

#Business & Investment #News

Bispecific antibodies
#Bispecific Antibodies #Dren Bio #Novartis #Oncology #Partnership

Novartis and Dren Bio partner on bispecific antibodies for cancer

Dren Bio and Novartis Pharma have entered a strategic collaboration focused on the discovery and development of therapeutic bispecific antibodies for cancer. Under the terms of the agreement, Dren Bio will receive a total upfront consideration of $150 million from Novartis, which includes a $25 million equity investment in the… Read More

#Business & Investment #News

#Arvinas #License agreement #Novartis #Prostate cancer #PROTAC #Protein degradation

Novartis buys Arvinas’ prostate cancer protein degrader for $150m

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 programme, a splice variant of the AR. Read More

#Business & Investment #News

Scotland
#Biologics #Dermatology #Novartis #Scottish Medicines Consortium (SMC)

New biologic approved in Scotland for hidradenitis suppurativa

Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. The advice applies for use in adult patients with… Read More

#News #Regulatory

Immunity
#Immunity #Neurology #Novartis #Sitting Down With

Sitting down with… Catherine Emond, Novartis  

Catherine Emond is the Head of Immunology and Neuroscience at Novartis UK. She is responsible for driving long-term strategies that can help change the lives of people with challenging immunological and neurological conditions. With over two decades of leadership experience, Emond is known for her broad brand lifecycle management achievements… Read More

#Exclusive Content

Sleeping sickness parasite
#Drug discovery #Novartis #Parasitic disease #University of Glasgow

Compound discovery has breakthrough potential for parasitic disease

Scientists have discovered a new class of compound that is potentially active against trypanosome parasites that cause human African trypanosomiasis (or sleeping sickness) and Chagas disease. The findings – led by researchers at the University of Glasgow and Novartis Global Health (formerly Novartis Institutes for Tropical… Read More

#News

Breast cancer
#ASCO #Breast cancer #Cancer research #Novartis #Oncology #Phase III trial

Drug reduced the risk of breast cancer recurrence by 25%

Positive primary endpoint data from Novartis’ pivotal Phase III NATALEE trial has been presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2%… Read More

#Cancer Research #News #Trending News

Prostate-specific membrane antigen
#Cancer research #Europe #Novartis #Oncology #Prostate cancer

New prostate cancer drug approved in Europe

A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen).   The drug was developed under the leadership of the German Cancer Research Center (DKFZ)… Read More

#Cancer Research #News #Trending News

Child having ultrasound on knee
#Arthritis #Juvenile idiopathic arthritis #MHRA #Novartis #Paediatrics #Phase III trial

UK MHRA expands Cosentyx use in paediatric arthritic conditions

The UK Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Novartis’ Cosentyx (secukinumab) in two types of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), and juvenile psoriatic arthritis (JPsA).  The drug is approved alone or in combination with methotrexate (MTX) in… Read More

#News

Chronic myeloid leukaemia
#Cancer research #European Commission #Leukaemia #Novartis #Orphan drugs #Scemblix #STAMP inhibitor

European Commission approval for chronic myeloid leukaemia drug

The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… Read More

#Cancer Research #News

Red blood cells
#Novartis #Scottish Medicines Consortium (SMC) #Sickle cell disorder (SCD)

First treatment for sickle cell side-effect in 20 years approved

The first new treatment in 20 years that prevents a common, painful side-effect in patients with sickle cell disorder (SCD) has been issued interim acceptance by the Scottish Medicines Consortium (SMC).  The SMC issued interim acceptance for Novartis UK’s Adakveo for use in NHS Scotland as a… Read More

#News

Stamp of approval
#Drug approvals #MHRA #Novartis #Oncology

MHRA approves Novartis treatment for CML  

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Novartis UK’s treatment for a specific type of cancer.  The authorisation was granted for Scemblix (asciminib), Novartis UK’s therapy for adults with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who have previously been treated… Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #Novartis

Stop, collaborate and listen: a model for successful pharma and vendor engagement

Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities and challenges. One of those challenges is adopting new software systems to drive the transformations. Pharma invests in powerful software technologies with the promise of increased efficiencies, but ultimately, if the interfaces are unintuitive and more… Read More

#Exclusive Content